-transparent.png){kind=logo}
The incidence and risk factors of chlorpropamide-induced hyponatremia were assessed in diabetic outpatients. In 176 chlorpropamide-treated patients, 11 (6.3%) exhibited hyponatremia (serum sodium less than or equal to 129 meq/L) during the mean follow-up period of 7.4 yr. In contrast, only one (0.6%) developed hyponatremia in 162 tolbutamide- or glibenclamide-treated patients (P less than 0.005). Moreover, administration to elderly patients and combination with thiazide diuretics were regarded as significantly potent risk factors for the development of hyponatremia in patients receiving chlorpropamide.
Related Publications
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
January 1972,
Duodecim; laaketieteellinen aikakauskirja,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
November 1976,
The Journal of clinical endocrinology and metabolism,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
November 1976,
Southern medical journal,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
October 1974,
Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
April 1972,
The New England journal of medicine,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
October 1992,
The Annals of pharmacotherapy,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
March 1972,
The American journal of the medical sciences,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
January 1971,
The New England journal of medicine,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
July 1978,
Schweizerische medizinische Wochenschrift,
T Kadowaki, and
R Hagura, and
H Kajinuma, and
N Kuzuya, and
S Yoshida
October 2022,
Journal of the Endocrine Society,
